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Abstract Extramammary Paget’s disease (EMPD) is a
rare intraepithelial neoplasm occurring less frequently in
men and even more rarely in the axilla. A 59-year-old man
with severe Parkinson’s disease presented with axillary
EMPD. The neurological comorbidity made treatment of
the EMPD problematical and prompted us to propose
locoregional intra-arterial chemotherapy in single short
sessions. Two innovative chemotherapeutic macrocom-
plexes were used: doxorubicin incorporated in large lipo-
somes and the taxane paclitaxel incorporated in albumin
nanoparticles. A therapeutic response was seen right from
the ﬁrst treatment and was macroscopically close to com-
plete after four cycles. Five months after the end of treat-
ment the patient had minimal visible disease and had
enjoyed a distinct improvement in quality of life, with no
noteworthy complications related to the intra-arterial che-
motherapy with percutaneous transfemoral catheterization.
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Introduction
Extramammary Paget’s disease (EMPD) is a somewhat
rare [1], initially intraepithelial neoplasm that grows slowly
but can become inﬁltrating and develop into a metasta-
sizing adenocarcinoma [2]. EMPD can occur in various
parts of the body, especially in those where the skin is rich
in apocrine and eccrine glands [3, 4]. The most common
treatment is surgical excision but the disease tends to recur
very easily, and in a certain percentage of cases (12%) it is
associated with a primary malignancy [2]. This neoplasm
has recently gained more attention, thanks to the progress
in diagnostic techniques and the application of new treat-
ment methods [5, 6].
Case Report
A 59-year-old man presented with an extensive cutaneous
lesion of the right axilla with symptoms of pruritus, irrita-
tion, burning sensation, and pain. His clinical history was
signiﬁcant for a ﬁnding of scoliosis at 18 years, appendec-
tomy at 48 years, thyroidectomy due to colloid-cystic goiter
at 57 years, and a diagnosis of progressive Parkinson’s
disease at58 years,currentlyunder treatmentwith levodopa
and catechol-O-methyltransferase inhibitors, with marginal
improvement. A partially ulcerated exophytic lesion with
irregular margins, reddish in color, with white plaques,
involved an area of 49 cm
2 in the right axilla (Fig. 1A). The
patient’s inability to attend to personal hygiene and the
massive oozing and unpleasant odor and symptoms
prompted his family, who had initially underestimated the
cutaneous lesion, to seek treatment. The patient refused
surgery but was persuaded to agree to biopsy (Fig. 1B, C).
Radiotherapy, laser treatment, systemic chemotherapy, and
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posed but proved impracticable. There was no evidence of
axillary lymphadenopathy and physical examination of the
chest was normal. CT of the thorax, abdomen, and pelvis
and complete blood tests, including tumor markers, were
performedto rule outan associated primarymalignancy.All
these tests were normal. The authors, who were consulted
because of their experience in locoregional treatments,
suggested intra-arterial chemotherapy with liposomal
doxorubicin (Myocet) and paclitaxel in albumin nanoparti-
cles (Abraxane).
Starting from January 2009, angiography (Fig. 1D) via
transfemoral catheterization of the right axillary artery (5-Fr
Envoy-H1 catheter; Cordis-Johnson&Johnson, Miami, FL,
USA) was carried out under sedation, and treatment was
given in four successive cycles at 4-week intervals. For each
treatment cycle 200 mg of Abraxane (American BioSci-
ence, Inc., Los Angeles, CA, USA) and 80 mg of Myocet
(Cephalon France, Maisons Alfort, France) were used. Each
drugwasdilutedin200 mlofnormalsalineandinfusedover
15 min. Counterpressure a little below the maximum arte-
rial pressure was applied by sphygmomanometer to the
humeral artery to reduce distal escape of drugs. After each
cycle therapeutic response was evaluated visually and
documented photographically and by angiography before
injection of the drugs (Fig. 2A–F). A complete blood count
was done weekly.
Blood counts always remained within normal limits.
Among the side effects were alopecia, transient general
weakness, and paresthesias of the right arm. Complete
blood counts showed no bone marrow depression requiring
correction with growth factors. An objective response with
minimal residual disease of the skin occurred 4 months
from the start of treatment and was maintained for the
5 months that passed from the end of treatment to the time
of writing (Fig. 3).
Discussion
EMPD of the axilla can be treated in various ways, which
are rarely conclusive, either singly or in combination,
because of the high frequency of recurrence [6]. The 5-year
survival rate without treatment is 59%. Survival falls to
Fig. 1 Paget’s disease of the
right axilla. A Photograph of the
patient upon presentation. Note
the copious oozing on the
surface of the neoplasm.
B, C Histology obtained with
excisional biopsy. ‘‘The skin
shows an intraepidermal
proliferation of large, atypical
epithelial elements, with
copious clear cytoplasm and a
vesiculate nucleus, positive for
cytockeratin and PAS and
negative for Melan-A, HMB-45,
and S-100.’’ D Transfemoral
angiogram of the axillary artery.
The Paget’s disease is intensely
vascularized, with a capillary
nest, and without evidence of
early venous drainage
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carcinoma at presentation [7]. The patient treated by the
authors had Parkinson’s disease with frequent tremors,
rigidity, and postural instability, which made him difﬁcult
to manage from both a practical and a psychological point
of view. Locoregional chemotherapy—to the authors’
knowledge, never used before to treat EMPD—was
considered feasible because of the high dose intensity that
can be achieved in single treatments, each of brief duration,
which can be given under sedation.
The active principles were chosen on the basis of the
similarity of EMPD to breast adenocarcinoma [7, 8], for
which doxorubicin and taxanes are recognized to be
effective. It was expected that greater tumor exposure
Fig. 2 Course of objective
response during intra-arterial
treatment of extramammary
Paget’s disease of the right
axilla with Myocet-Abraxane.
After the second treatment
cycle: reduction in pathological
vascularization at angiography
(A) and reduced size of the skin
lesion (B). C, D After the third
cycle. E, F After the fourth
cycle
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liposomes and albumin nanoparticles—measuring 150–
200 nm in diameter, because of the tumor’s substantial
vascular network. In this setting, the so-called enhanced
permeability and retention (EPR) effect occurs, whereby
macrocomplexes pass through the discontinuous endothe-
lium of tumor capillaries and maintain prolonged contact
with the tumor cells because of the lack of effective lym-
phatic drainage toward the general circulation [9, 10]. This
leads to high tumor exposure to the drugs with reduced
systemic exposure. Liposome-encapsulated doxorubicin
differs from conventional doxorubicin in its pharmacoki-
netic and therapeutic behavior. In practice, liposomes can
be considered as a transport system which allows release of
doxorubicin where greater vascular permeability occurs.
Paclitaxel in albumin nanoparticles exploits the same
transport mechanism, with the added advantage that albu-
min is used for tumor growth, representing the main source
of energy for tumor cells. Once the cell membrane has been
crossed, the taxane is released, interfering with the tubular
apparatus and causing cell death.
In the present case, treatment was not associated with
major complications related to percutaneous catheteriza-
tion or drug toxicity, ensuring a distinct improvement in
the patient’s quality of life. This objective result could
suggest consideration of intra-arterial chemotherapy as a
neoadjuvant treatment for EMPD before surgical resection
or laser vaporization or concurrently with radiotherapy.
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Fig. 3 Further improvement in appearance of the skin lesion
5 months after the end of treatment
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